News from NORD

NORD Launches Year-Long 35th Anniversary Observance


 

2018 marks the 35th anniversary of the Orphan Drug Act (ODA) and of NORD. The ODA was signed into law by President Ronald Reagan on January 4, 1983. Exactly four months later, NORD was formally established by the patient organization leaders who had provided advocacy for the ODA. The ODA provides critically important financial incentives to encourage development of treatments for rare diseases. Major events during the anniversary year will include NORD’s Rare Impact Awards in May and Rare Summit in October. Visit the NORD website often this year for information about those and other anniversary activities.

Recommended Reading

Nominate a Colleague or Patient for a NORD Rare Impact Award
MDedge Dermatology
NORD Reopens Call for Abstracts for Research Grants
MDedge Dermatology
Poster Abstracts Due January 31 for European Conference on Rare Diseases and Orphan Products
MDedge Dermatology
Beta Version of ClinicalTrials.gov Website Available for Public Testing
MDedge Dermatology
NORD Welcomes Five New Member Organizations
MDedge Dermatology
Rituximab tackles relapse of severe, difficult-to-treat pemphigus
MDedge Dermatology
Join 7,000 Miles Campaign to Support Programs for Rare Disease Patients
MDedge Dermatology
January 12 Is Deadline for Rare Impact Awards Nominations
MDedge Dermatology
NORD Awards Five Research Grants
MDedge Dermatology
Visit NORD’s Website to Learn About Current or Future Research Funding Opportunities
MDedge Dermatology